首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 製藥企業 > 全球醫療相關企業各治療領域間的合作:2006 年版 第二卷
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

全球醫療相關企業各治療領域間的合作:2006 年版 第二卷

Partneringreview 2006 - Therapy area (volume 2)

出版商 Pharmalicensing Ltd.
出版日期 2006年02月 商品編碼 36673
內容資訊 英文 1802 pages
價格
US $ 2495 PDF by E-mail (Single User License)


全球醫療相關企業各治療領域間的合作:2006 年版 第二卷 是由出版商Pharmalicensing Ltd.在2006年02月所出版的。 這份英文市場調查報告書包含1802 pages 價格從美金2495起跳。

簡介

2005 年生技藥物領域的企業合併與吸收持續進展,件數達到 230 件,較 2004、2003 年的 170、150 件都來得多。

專研製藥、生技、保健領域,素有好評的英國市調公司 Pharmalicensing (總公司:英國雷斯塔夏),調查分析了全球醫療相關企業各治療領域 間的合作後,出版了一本綜合報告書 "Partneringreview 2006 - Therapy area (volume 2)"

本報告書為全系列六卷中的第二卷,內容包含 2,600 件以上的企業合作,分類為癌症、感染疾病、心臟血管疾病、循環器官疾病、中樞神經疾病、自我免疫疾病等等,內容綱要摘記如下:

第1章 癌症

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第2章 感染疾病

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第3章 心臟血管疾病與循環器官疾病

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第4章 中樞神經疾病

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第5章 自我免疫與發炎

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第6章 代謝治療

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第7章 呼吸器官疾病

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第8章 腸胃疾病

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第9章 肌肉骨骼疾病

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第10章 感覺器官與口腔疾病

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第11章 泌尿與婦科疾病

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第12章 皮膚科疾病

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第13章 血液、淋巴疾病

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第14章 事故、醫院、外傷

  • 各企業合作
  • 各產業領域合作
  • 各研發階段合作

第15章 合作列表

用語

目錄

Abstract

Partneringreview 2006 -- Volume 2: Therapy area provides an in depth view into the deals and alliances by therapeutic area announced in 2005, in a clear and accessible format. The report reviews over 2,600 deal announcements in therapeutic areas - oncology, infectious disease, cardiovascular, circulatory, central nervous system, autoimmune, inflammation, metabolism, respiratory, gastrointestinal, musculoskeletal, sensory organ, oral health, genitourinary, gynecology, dermatology, blood system, lymphatic system, and accident/hospital/trauma.

Each sector is further divided to analyze deals by company, industry sector, and stage of development. Every deal is fully categorized, includes a detailed description, and includes financials such as headline value, upfront and milestone payments, where disclosed. Each deal is annotated with a deal number, such as #43. This number links to the full deal in the deal listing at the rear of each report. When using the PDF format in Acrobat Reader, simply click on the number to move around the report.

All the year's deals at a glance.

Want to know what your competitors are doing? Want to benchmark your deals against others in your therapeutic area or see how the finances of different deal types compare? Partneringreview 2006 brings all the 2005's deals into focus in one place.

Partneringreview is a comprehensive summary of the year's deal announcements in a clear and accessible printable format. Every deal entry includes financial information where disclosed, such as headline values and upfront and milestone payments. A new addition of an overview of financings from investors is also included in this latest edition.

Partneringreview 2006 is the full report of all the deals data collected in 2005, providing a broad perspective of deal announcements, and incorporates all six volumes.

Table of Contents

INTRODUCTION

  • About Partneringreview
  • Full contents of Partneringreview 2006
  • Review of deal making in 2005
  • Deals announced by therapy area

VOLUME 2: THERAPY AREA

Chapter 1: Oncology

  • Deals in the oncology therapy area by company
  • Deals in the oncology therapy area by industry focus
  • Deals in the oncology therapy area by development stage

Chapter 2: Infectious disease

  • Deals in the infectious disease therapy area by company
  • Deals in the infectious disease therapy area by industry focus
  • Deals in the infectious disease therapy area by development stage

Chapter 3: Cardiovascular/Circulatory

  • Deals in the cardiovascular/circulatory therapy area by company
  • Deals in the cardiovascular/circulatory therapy area by industry focus
  • Deals in the cardiovascular/circulatory therapy area by development stage

Chapter 4: Central Nervous System

  • Deals in the central nervous system therapy area by company
  • Deals in the central nervous system therapy area by industry focus
  • Deals in the central nervous system therapy area by development stage

Chapter 5: Autoimmune/Inflammation

  • Deals in the autoimmune/inflammation therapy area by company
  • Deals in the autoimmune/inflammation therapy area by industry focus
  • Deals in the autoimmune/inflammation therapy area by development stage

Chapter 6: Metabolism

  • Deals in the metabolism therapy area by company
  • Deals in the metabolism therapy area by industry focus
  • Deals in the metabolism therapy area by development stage

Chapter 7: Respiratory

  • Deals in the respiratory therapy area by company
  • Deals in the respiratory therapy area by industry focus
  • Deals in the respiratory therapy area by development stage

Chapter 8: Gastrointestinal

  • Deals in the gastrointestinal therapy area by company
  • Deals in the gastrointestinal therapy area by industry focus
  • Deals in the gastrointestinal therapy area by development stage

Chapter 9: Musculoskeletal

  • Deals in the musculoskeletal therapy area by company
  • Deals in the musculoskeletal therapy area by industry focus
  • Deals in the musculoskeletal therapy area by development stage

Chapter 10: Sensory Organ/Oral Health

  • Deals in the sensory organ/oral health therapy area by company
  • Deals in the sensory organ/oral health therapy area by industry focus
  • Deals in the sensory organ/oral health therapy area by development stage

Chapter 11: Genitourinary/Gynecology

  • Deals in the genitourinary/gynecology therapy area by company
  • Deals in the genitourinary/gynecology therapy area by industry focus
  • Deals in the genitourinary/gynecology therapy area by development stage

Chapter 12: Dermatology

  • Deals in the dermatology therapy area by company
  • Deals in the dermatology therapy area by industry focus
  • Deals in the dermatology therapy area by development stage

Chapter 13: Blood/Lymphatic System

  • Deals in the blood/lymphatic system therapy area by company
  • Deals in the blood/lymphatic system therapy area by industry focus
  • Deals in the blood/lymphatic system therapy area by development stage

Chapter 14: Accident/Hospital/Trauma

  • Deals in the accident/hospital/trauma therapy area by company
  • Deals in the accident/hospital/trauma therapy area by industry focus
  • Deals in the accident/hospital/trauma therapy area by development stage

Chapter 15: List of deals

GLOSSARY

Tables

  • Table 1 Top oncology area dealmaking companies in 2005
  • Table 2 Top infectious disease area dealmaking companies in 2005
  • Table 3 Top cardiovascular/circulatory area dealmaking companies in 2005
  • Table 4 Top central nervous system area dealmaking companies in 2005
  • Table 5 Top autoimmune/inflammation area dealmaking companies in 2005
  • Table 6 Top metabolism area dealmaking companies in 2005
  • Table 7 Top respiratory area dealmaking companies in 2005
  • Table 8 Top gastrointestinal area dealmaking companies in 2005
  • Table 9 Top musculoskeletal area dealmaking companies in 2005
  • Table 10 Top sensory organ/oral health area dealmaking companies in 2005
  • Table 11 Top genitourinary/gynecology area dealmaking companies in 2005
  • Table 12 Top dermatology area dealmaking companies in 2005
  • Table 13 Top blood/lymphatic system area dealmaking companies in 2005
  • Table 14 Top accident/hospital/trauma area dealmaking companies in 2005

Figures

  • Fig. i.1 Deals announced by therapy focus
  • Fig. 1.1 Announcements in the oncology therapy area by company
  • Fig. 1.2 Announcements in the oncology therapy area by industry sector
  • Fig. 1.3 Announcements in the oncology therapy area by development stage
  • Fig. 2.1 Announcements in the infectious disease therapy area by company
  • Fig. 2.2 Announcements in the infectious disease therapy area by industry sector
  • Fig. 2.3 Announcements in the infectious disease therapy area by development stage
  • Fig. 3.1 Announcements in the cardiovascular/circulatory therapy area by company
  • Fig. 3.2 Announcements in the cardiovascular/circulatory therapy area by industry sector
  • Fig. 3.3 Announcements in the cardiovascular/circulatory therapy area by development
  • Fig. 4.1 Announcements in the central nervous system therapy area by company
  • Fig. 4.2 Announcements in the central nervous system therapy area by industry sector
  • Fig. 4.3 Announcements in the central nervous system therapy area by development stage
  • Fig. 5.1 Announcements in the autoimmune/inflammation therapy area by company
  • Fig. 5.2 Announcements in the autoimmune/inflammation therapy area by industry sector
  • Fig. 5.3 Announcements in the autoimmune/inflammation therapy area by development stage
  • Fig. 6.1 Announcements in the metabolism therapy area by company
  • Fig. 6.2 Announcements in the metabolism therapy area by industry sector
  • Fig. 6.3 Announcements in the metabolism therapy area by development stage
  • Fig. 7.1 Announcements in the respiratory therapy area by company
  • Fig. 7.2 Announcements in the respiratory therapy area by industry sector
  • Fig. 7.3 Announcements in the respiratory therapy area by development stage
  • Fig. 8.1 Announcements in the gastrointestinal therapy area by company
  • Fig. 8.2 Announcements in the gastrointestinal therapy area by industry sector
  • Fig. 8.3 Announcements in the gastrointestinal therapy area by development stage
  • Fig. 9.1 Announcements in the musculoskeletal therapy area by company
  • Fig. 9.2 Announcements in the musculoskeletal therapy area by industry sector
  • Fig. 9.3 Announcements in the musculoskeletal therapy area by development stage
  • Fig. 10.1 Announcements in the sensory organ/oral health therapy area by company
  • Fig. 10.2 Announcements in the sensory organ/oral health therapy area by industry sector
  • Fig. 10.3 Announcements in the sensory organ/oral health therapy area by development
  • Fig. 11.1 Announcements in the genitourinary/gynecology therapy area by company
  • Fig. 11.2 Announcements in the genitourinary/gynecology therapy area by industry sector
  • Fig. 11.3 Announcements in the genitourinary/gynecology therapy area by development
  • Fig. 12.1 Announcements in the dermatology therapy area by company
  • Fig. 12.2 Announcements in the dermatology therapy area by industry sector
  • Fig. 12.3 Announcements in the dermatology therapy area by development stage
  • Fig. 13.1 Announcements in the blood/lymphatic system therapy area by company
  • Fig. 13.2 Announcements in the blood/lymphatic system therapy area by industry sector
  • Fig. 13.3 Announcements in the blood/lymphatic system therapy area by development stage
  • Fig. 14.1 Announcements in the accident/hospital/trauma therapy area by company
  • Fig. 14.2 Announcements in the accident/hospital/trauma therapy area by industry sector
  • Fig. 14.3 Announcements in the accident/hospital/trauma therapy area by development
Back to Top